Replimune Group Inc(REPL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.28 | Insider Own | 7.18% | Shs Outstand | 94.2M | Perf Week | -17.21% |
| Market Cap | 1.25B | Forward P/E | - | EPS next Y | 27.01% | Insider Trans | -2.75% | Shs Float | 87.5M | Perf Month | -3.08% |
| Enterprise Value | 1.16B | PEG | - | EPS next Q | -0.78 | Inst Own | 102.95% | Short Float | 28.44% | Perf Quarter | 56.2% |
| Income | -0.30B | P/S | - | EPS this Y | 16.77% | Inst Trans | 18.61% | Short Ratio | 5.5 | Perf Half Y | 67.47% |
| Sales | 0.00B | P/B | 10.52 | EPS next 5Y | 40.56% | ROA | -82.28% | Short Interest | 24.87M | Perf YTD | 36.11% |
| Book/sh | 1.26 | P/C | 6.38 | EPS past 3/5Y | -4.15% -14.11% | ROE | -134.29% | 52W High | -18.98% ($16.33) | Perf Year | 120.87% |
| Cash/sh | 2.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -139.06% | 52W Low | 782% ($1.50) | Perf 3Y | -32.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.95% | Gross Margin | - | Volatility(W/M) | 4.29% 5.91% | Perf 5Y | -58.68% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.23 | EPS Q/Q | 23.97% | Profit Margin | - | RSI (14) | 43.98 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.23 | Sales Q/Q | - | SMA20 | -12.16% ($15.06) | Beta | 0.93 | Target Price | $19.43 |
| Payout | - | Debt/Eq | 1.06 | Earnings | 2026/8/14 | SMA50 | 5.56% ($12.53) | Rel Volume | 0.81 | Prev Close | $14.45 |
| Employees | 465 | LT Debt/Eq | 1.02 | EPS/Sales Surpr. | -3.75% - | SMA200 | 52.23% ($8.69) | Avg Volume(3M) | 4.52M | Price | $13.23 |
| IPO | 2018/7/20 | Option/Short | Yes/Yes | Trades | 24025 | Volume | 3,641,836 | Change | -8.44% |
Company
REPL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Replimune Group (REPL) is a US biotech company developing immune oncology therapies based on tumor-dissolving (oncolytic) viruses. Founded in 2015, the company is researching treatments for solid tumors such as melanoma using its RPx platform, which combines an engineered herpes simplex virus with immune-modulating genes. This approach aims to directly activate anti-cancer immune responses within the tumor itself, and Replimune is pursuing combination strategies with existing immune checkpoint inhibitors.
Over the past 1 year, on the higher side
19% below its 1-year high.
REPL has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +16.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -32.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 103.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
MEDX 0.01%
DWAS 0.00%
XBI 0.00%
SMIZ 0.00%
BBC 0.00%It ranks #4 in the industry
Based on market cap of $1B.
REPL $1B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is REPL?
REPL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of REPL?
The market cap of REPL is approximately $1.2B, ranking 2,468 within its sector.
What is the 52-week high and low for REPL?
REPL has recorded a 52-week high of $16.33 and a low of $1.50.
